https://vaticanhealthtimes.com/article/910266581-flyte-increases-capacity-and-launches-hiring-initiative-as-spirit-airlines-shutdown-disrupts-u-s-air-travel Vatican Health Times en PressRelease 2026-05-04T14:30:00+00:00 Flyte Increases Capacity and Launches Hiring Initiative as Spirit Airlines Shutdown Disrupts U.S. Air Travel https://ml.globenewswire.com/media/cb9f10dc-be78-4c7c-a235-81bfdd77f03c/small/catheterlogo-jpg.jpg https://vaticanhealthtimes.com/article/910266602-chopped-leaf-launches-new-premium-sandwich-lineup-featuring-toasted-ciabatta-creations Vatican Health Times en PressRelease 2026-05-04T14:24:08+00:00 Chopped Leaf Launches New Premium Sandwich Lineup Featuring Toasted Ciabatta Creations https://ml.globenewswire.com/media/ZGY0ZWI1OTEtNGNhNy00ZmFjLThhN2EtODM5YTdmNmVkMDUxLTEyNzIxMjEtMjAyNi0wNS0wNC1lbg==/tiny/The-Chopped-Leaf.png https://vaticanhealthtimes.com/article/910262632-mmi-s-symani-surgical-system-treats-first-alzheimer-s-patient-in-groundbreaking-remind-study Vatican Health Times en PressRelease 2026-05-04T14:10:00+00:00 MMI’s Symani Surgical System Treats First Alzheimer’s Patient in Groundbreaking REMIND Study https://ml.globenewswire.com/media/e9325bed-8fcb-4abf-b66e-6f076014b0fb/small/mmi-logo-stacked-tagline-positive-rgb1-png.png https://vaticanhealthtimes.com/article/910262611-research-on-new-class-of-treatments-for-ovarian-cancer-receives-725-000-in-funding-from-ovarian-cancer-canada-to-become-clinical-trial-ready Vatican Health Times en PressRelease 2026-05-04T14:00:00+00:00 Research on new class of treatments for ovarian cancer receives $725,000 in funding from Ovarian Cancer Canada to become “clinical trial-ready” https://ml.globenewswire.com/media/YWY2NGZiYWEtODcyZC00Y2I5LThkZGEtYmM5ZjlkYzFkNDMzLTEzMTI5NjUtMjAyNi0wNS0wNC1lbg==/tiny/Ovarian-Cancer-Canada.png https://vaticanhealthtimes.com/article/910262626-spring-allergies-hit-lungs-hard-doctor-of-pharmacy-explains-what-actually-helps Vatican Health Times en PressRelease 2026-05-04T14:00:00+00:00 Spring Allergies Hit Lungs Hard: Doctor of Pharmacy Explains What Actually Helps https://ml.globenewswire.com/media/13a92186-d8d0-4494-9e0a-5fc1d2e363ee/small/betterbrand-logo-new-png.png https://vaticanhealthtimes.com/article/910262571-xpress-wellness-acquires-wichita-s-mental-health-clinic-midwest-counseling-services Vatican Health Times en PressRelease 2026-05-04T13:57:00+00:00 Xpress Wellness Acquires Wichita’s Mental Health Clinic Midwest Counseling Services https://ml.globenewswire.com/media/3c8097b3-a387-4dd0-8063-4f48aad75699/small/xpress-wellness-logo-png.png https://vaticanhealthtimes.com/article/910258243-cdc-host-tt-certification-for-siemens-healthineers-total-testosterone-test-expands-patient-access-to-gold-standard-equivalent-results Vatican Health Times en PressRelease 2026-05-04T13:30:00+00:00 CDC HoST-TT Certification for Siemens Healthineers Total Testosterone Test Expands Patient Access to Gold Standard Equivalent Results https://ml.globenewswire.com/media/c5f289d1-b23c-41d2-bfe1-0121523d54b6/small/ https://vaticanhealthtimes.com/article/910258255-coherus-oncology-to-report-first-quarter-2026-financial-results-on-may-11-2026 Vatican Health Times en PressRelease 2026-05-04T13:30:00+00:00 Coherus Oncology to Report First Quarter 2026 Financial Results on May 11, 2026 https://ml.globenewswire.com/media/07437af0-8ae3-48cf-952b-18bc6b99ca7c/small/coherus-onc-logo-rgb-150-png.png https://vaticanhealthtimes.com/article/910258286-alpha-tau-announces-100-local-disease-control-rate-and-favorable-safety-profile-observed-in-alpha-dart-pancreatic-cancer-trials-presented-at-ddw Vatican Health Times en PressRelease 2026-05-04T13:17:21+00:00 Alpha Tau Announces 100% Local Disease Control Rate and Favorable Safety Profile Observed in Alpha DaRT® Pancreatic Cancer Trials Presented at DDW 2026 https://ml.globenewswire.com/media/a9de6f03-a487-4934-98e9-d25cdb4c8bed/small/atm-logo-jpg.jpg https://vaticanhealthtimes.com/article/910253033-greece-launches-world-s-first-national-wildfire-satellite-system-with-ororatech Vatican Health Times en PressRelease 2026-05-04T13:04:00+00:00 Greece Launches World’s First National Wildfire Satellite System with OroraTech https://ml.globenewswire.com/media/f405d4dd-2633-4e23-8086-bbaa6bf83b25/medium/ororatech-s-hellenic-fire-system.jpg https://vaticanhealthtimes.com/article/910253114-aura-biosciences-announces-pricing-of-260-million-public-offering-of-common-stock-and-pre-funded-warrants Vatican Health Times en PressRelease 2026-05-04T13:03:06+00:00 Aura Biosciences Announces Pricing of $260 Million Public Offering of Common Stock and Pre-funded Warrants https://ml.globenewswire.com/media/92103c30-8e5a-4502-9ec4-0f3b3bd9bb83/small/aura-biosciences-1c-orange-large-jpg.jpg https://vaticanhealthtimes.com/article/910252862-carnosyn-brands-expands-tribsyn-applications-across-beverage-dairy-and-medical-nutrition Vatican Health Times en PressRelease 2026-05-04T13:00:00+00:00 CarnoSyn® Brands Expands TriBsyn® Applications Across Beverage, Dairy, and Medical Nutrition https://ml.globenewswire.com/media/4b40dd5b-0137-41f8-83de-422e4b4f3196/small/nai-full-logo-green2-0-png.png https://vaticanhealthtimes.com/article/910252869-oncolytics-biotech-reports-durable-responses-in-second-line-ras-mutant-mss-colorectal-cancer Vatican Health Times en PressRelease 2026-05-04T13:00:00+00:00 Oncolytics Biotech® Reports Durable Responses in Second-Line RAS-Mutant MSS Colorectal Cancer https://ml.globenewswire.com/media/f0121259-b2be-4290-90a3-0d2c3b243aed/small/oncolytics-biotech-jpg.jpg https://vaticanhealthtimes.com/article/910252878-curated-digital-health-works-now-there-s-a-claims-study-to-prove-it Vatican Health Times en PressRelease 2026-05-04T13:00:00+00:00 Curated Digital Health Works; Now There’s a Claims Study to Prove It https://ml.globenewswire.com/media/b8d88974-2aeb-4baa-ad3b-2ab758ed4dd9/small/solera-main-logo-red-png.png https://vaticanhealthtimes.com/article/910252958-biomogging-brings-research-backed-rigour-to-looksmaxxing-as-the-discipline-goes-mainstream Vatican Health Times en PressRelease 2026-05-04T13:00:00+00:00 BioMogging Brings Research-Backed Rigour to Looksmaxxing as the Discipline Goes Mainstream https://ml.globenewswire.com/media/70c5dbfa-bae7-4e93-ac79-cd20cb471a59/medium/biomogging-brings-research-backed-rigour-to-looksmaxxing-as.png https://vaticanhealthtimes.com/article/910252971-fate-therapeutics-announces-three-presentations-at-the-2026-asgct-annual-meeting-highlighting-off-the-shelf-car-t-cell-therapy-pipeline-for-cancer-and Vatican Health Times en PressRelease 2026-05-04T13:00:00+00:00 Fate Therapeutics Announces Three Presentations at the 2026 ASGCT Annual Meeting Highlighting Off-the-Shelf CAR T-cell Therapy Pipeline for Cancer and Autoimmune Diseases https://ml.globenewswire.com/media/2acb7cd9-5f5c-42d0-a606-72d085e2fe6e/small/fate-therapeutics-jpg.jpg https://vaticanhealthtimes.com/article/910253043-gyre-therapeutics-completes-acquisition-of-cullgen-to-create-u-s-and-china-based-fully-integrated-biopharmaceutical-company Vatican Health Times en PressRelease 2026-05-04T12:47:47+00:00 Gyre Therapeutics Completes Acquisition of Cullgen to Create U.S.- and China-based Fully Integrated Biopharmaceutical Company https://ml.globenewswire.com/media/24951768-57e9-4d7a-b969-f00258b17136/small/gyre-logo-png.png https://vaticanhealthtimes.com/article/910252933-cannabix-technologies-announces-delivery-of-marijuana-breath-test-mbt-to-workplace-drug-and-alcohol-testing-clinic Vatican Health Times en PressRelease 2026-05-04T12:45:00+00:00 Cannabix Technologies Announces Delivery of Marijuana Breath Test (MBT) to Workplace Drug and Alcohol Testing Clinic https://ml.globenewswire.com/media/72457dcd-4783-441b-b82d-641591cd1f13/medium/cannabix-technologies-inc.jpg https://vaticanhealthtimes.com/article/910253010-polyrizon-announces-u-s-patent-expansion-for-its-intranasal-drug-delivery-platform Vatican Health Times en PressRelease 2026-05-04T12:45:00+00:00 Polyrizon Announces U.S. Patent Expansion for Its Intranasal Drug Delivery Platform https://ml.globenewswire.com/media/YWIxMzIzNDgtN2UwNy00NTAyLThjZDMtZWMwNGFjZTdmNWJhLTUwMDEyOTIyMy0yMDI2LTA1LTA0LWVu/tiny/Polyrizon-Ltd-.png https://vaticanhealthtimes.com/article/910247536-brainway-launches-personalized-anti-procrastination-app-grounded-in-cbt-earns-6-000-user-reviews Vatican Health Times en PressRelease 2026-05-04T12:30:00+00:00 Brainway Launches Personalized Anti-Procrastination App Grounded in CBT, Earns 6,000+ User Reviews https://ml-eu.globenewswire.com/media/59f7037f-6f10-4f4b-9b8f-6a7b25f61828/medium/brainway-smarter-focus-built-around-you.png https://vaticanhealthtimes.com/article/910247553-mapi-pharma-explores-u-s-aseptic-manufacturing-facility-to-support-growing-demand-for-aseptic-and-long-acting-generic-and-innovative-injectables Vatican Health Times en PressRelease 2026-05-04T12:30:00+00:00 Mapi Pharma Explores U.S. Aseptic Manufacturing Facility to Support Growing Demand for Aseptic and Long-Acting Generic and innovative Injectables https://ml.globenewswire.com/media/a15e698a-0f26-4d44-bf6a-78b7ae34d25d/small/mapi-pharma-logo-png.png https://vaticanhealthtimes.com/article/910247597-abeona-therapeutics-announces-date-of-first-quarter-financial-results Vatican Health Times en PressRelease 2026-05-04T12:30:00+00:00 Abeona Therapeutics® Announces Date of First Quarter Financial Results https://ml.globenewswire.com/media/f11f9f14-9744-4666-aef3-9771488c41bd/small/thumb-1740-12-silhouette-vertical-full-color-png.png https://vaticanhealthtimes.com/article/910247598-sienna-continues-platform-growth Vatican Health Times en PressRelease 2026-05-04T12:30:00+00:00 Sienna Continues Platform Growth https://ml.globenewswire.com/media/ac969f39-0111-4903-8faa-0cdee524eb4e/small/sienna-logo-rgb-jpg.jpg https://vaticanhealthtimes.com/article/910247606-dentsply-sirona-launches-smart-view-detect-world-s-first-fda-cleared-ai-enabled-diagnostic-aid-for-detecting-teeth-with-periapical-radiolucencies Vatican Health Times en PressRelease 2026-05-04T12:30:00+00:00 Dentsply Sirona Launches Smart View - Detect, World’s First FDA-Cleared AI-enabled diagnostic aid for detecting teeth with Periapical Radiolucencies in CBCTs https://ml.globenewswire.com/media/91e36dfa-44e3-4905-a186-3a988bd67ab8/small/dentsply-sirona-grey-80-black-rgb-jpg.JPG https://vaticanhealthtimes.com/article/910247610-fibrobiologics-announces-release-of-cywc628-drug-product-for-phase-1-2-diabetic-foot-ulcer-clinical-trial Vatican Health Times en PressRelease 2026-05-04T12:30:00+00:00 FibroBiologics Announces Release of CYWC628 Drug Product for Phase 1/2 Diabetic Foot Ulcer Clinical Trial https://ml.globenewswire.com/media/720fe0fe-52b4-4ccc-a5ad-95d4288f1df2/small/fibrobiologics-logo-2022-jpg.jpg https://vaticanhealthtimes.com/article/910247613-bicara-therapeutics-to-report-first-quarter-2026-financial-results-and-business-updates-on-may-11-2026-at-8-30-am-et Vatican Health Times en PressRelease 2026-05-04T12:30:00+00:00 Bicara Therapeutics to Report First Quarter 2026 Financial Results and Business Updates on May 11, 2026, at 8:30 AM ET https://ml.globenewswire.com/media/fdf5e06f-0748-428a-8f90-b0a1c6f7bdf3/small/bicara-logo-struck-png.png https://vaticanhealthtimes.com/article/910247630-fortress-biotech-to-participate-in-the-h-c-wainwright-2nd-annual-royalty-company-virtual-conference Vatican Health Times en PressRelease 2026-05-04T12:30:00+00:00 Fortress Biotech to Participate in the H.C. Wainwright 2nd Annual Royalty Company Virtual Conference https://ml.globenewswire.com/media/d82bf2ce-81b7-4989-9e6b-08e6bb6e1f95/small/fortressbio1-jpg.jpg https://vaticanhealthtimes.com/article/910247674-newgen-provides-update-on-fiscal-year-2025-results-and-strategic-progress Vatican Health Times en PressRelease 2026-05-04T12:30:00+00:00 NewGen Provides Update on Fiscal Year 2025 Results and Strategic Progress https://ml.globenewswire.com/media/ZWQwY2VjNmQtYTdlZi00YTUxLTg3NmItMmI3OWVkMTQ5MGQ4LTEyOTcwMTEtMjAyNi0wNS0wNC1lbg==/tiny/NewGenIvf-Limited.png https://vaticanhealthtimes.com/article/910242525-serefin-health-launches-mycaresteps-program-to-support-care-coordination-across-grey-bruce Vatican Health Times en PressRelease 2026-05-04T12:05:00+00:00 Serefin Health Launches MyCareSteps Program to Support Care Coordination Across Grey Bruce https://ml.globenewswire.com/media/NmJiMmQwN2MtYTlmMi00Njc1LTk1N2QtNmZlYzk1MDJkMTc3LTEzMjMwMzktMjAyNi0wNS0wNC1lbg==/tiny/Serefin-Inc.png https://vaticanhealthtimes.com/article/910242598-candel-therapeutics-to-host-investor-conference-call-following-presentation-of-extended-data-from-phase-3-trial-of-aglatimagene-besadenovec-in Vatican Health Times en PressRelease 2026-05-04T12:05:00+00:00 Candel Therapeutics to Host Investor Conference Call Following Presentation of Extended Data from Phase 3 Trial of Aglatimagene Besadenovec in Localized Prostate Cancer at the American Urological Association 2026 Annual Meeting https://ml.globenewswire.com/media/8b82e1e3-4a67-4472-a7c8-05f9d24c9bb0/small/candel-logo-fullcolor-4-png.png https://vaticanhealthtimes.com/article/910242367-proqr-announces-annual-general-meeting-of-shareholders-to-be-held-june-2-2026 Vatican Health Times en PressRelease 2026-05-04T12:00:00+00:00 ProQR Announces Annual General Meeting of Shareholders to be Held June 2, 2026 https://ml-eu.globenewswire.com/media/f5ae7794-bff7-44dc-8709-0e9c3a9eac77/small/logo-proqr-150x150-png.png https://vaticanhealthtimes.com/article/910242370-dr-falk-pharma-and-renexxion-announce-positive-results-on-naronapride-in-gastroparesis-from-the-global-phase-2b-move-it-trial Vatican Health Times en PressRelease 2026-05-04T12:00:00+00:00 Dr. Falk Pharma and Renexxion announce positive results on naronapride in gastroparesis from the global phase 2b MOVE-IT trial https://ml-eu.globenewswire.com/media/7cf77d4a-25b5-4471-a282-0334907cbfbd/small/falk-logo-rgb-jpg.jpg https://vaticanhealthtimes.com/article/910242372-dr-falk-pharma-and-renexxion-announce-positive-results-on-naronapride-in-gastroparesis-from-the-global-phase-2b-move-it-trial Vatican Health Times en PressRelease 2026-05-04T12:00:00+00:00 Dr. Falk Pharma and Renexxion announce positive results on naronapride in gastroparesis from the global phase 2b MOVE-IT trial https://ml-eu.globenewswire.com/media/540f0a78-db35-42ad-9e90-7b81e8ff3ad6/small/renirl-logo-png.png https://vaticanhealthtimes.com/article/910242373-cptx-to-present-preclinical-proof-of-principle-of-its-dna-based-in-vivo-car-t-platform-at-asgct-annual-meeting Vatican Health Times en PressRelease 2026-05-04T12:00:00+00:00 CPTx to present preclinical proof-of-principle of its DNA-based in vivo CAR T platform at ASGCT Annual Meeting https://ml-eu.globenewswire.com/media/b3ec9ca7-8866-466a-9d91-09342002e341/small/cptx-logo-high-res-png.png https://vaticanhealthtimes.com/article/910242419-evaxion-to-announce-business-update-and-first-quarter-2026-financial-results-on-may-7-2026 Vatican Health Times en PressRelease 2026-05-04T12:00:00+00:00 Evaxion to announce business update and first quarter 2026 financial results on May 7, 2026 https://ml-eu.globenewswire.com/media/19d0d69c-7f37-4d3b-8f26-2866d4ec3311/small/evaxion-deepblue-rgb-png.png https://vaticanhealthtimes.com/article/910242435-recludix-pharma-announces-upcoming-oral-presentations-on-preclinical-data-for-oral-stat6-inhibitor-rex-8756-and-topical-stat-1-3-inhibitors-at-the Vatican Health Times en PressRelease 2026-05-04T12:00:00+00:00 Recludix Pharma Announces Upcoming Oral Presentations on Preclinical Data for Oral STAT6 Inhibitor REX-8756 and Topical STAT 1/3 Inhibitors at the Society for Investigative Dermatology (SID) Annual Meeting https://ml.globenewswire.com/media/NDM5ZGUzYTItNGI0Zi00N2Y3LWE3Y2QtZmViNDYyN2I1ZWRjLTEyMzYyMjItMjAyNi0wNS0wNC1lbg==/tiny/Recludix-Pharma-Inc-.png https://vaticanhealthtimes.com/article/910242438-rhythm-pharmaceuticals-announces-new-data-presentations-in-acquired-hypothalamic-obesity-at-pediatric-endocrine-society Vatican Health Times en PressRelease 2026-05-04T12:00:00+00:00 Rhythm Pharmaceuticals Announces New Data Presentations in Acquired Hypothalamic Obesity at Pediatric Endocrine Society https://ml.globenewswire.com/media/b767aaa5-9915-465f-9233-d97757f4e387/small/rhythm-logo-rgb-jpg-registration-mark-jpg.jpg https://vaticanhealthtimes.com/article/910242442-spur-therapeutics-presents-clinical-insights-on-bone-disease-impact-of-flt201-in-adults-with-gaucher-disease-type-1 Vatican Health Times en PressRelease 2026-05-04T12:00:00+00:00 Spur Therapeutics Presents Clinical Insights on Bone Disease Impact of FLT201 in Adults with Gaucher Disease Type 1 https://ml.globenewswire.com/media/195ccecc-f977-4fb5-ba01-43af7ec47589/small/spur-therapeutics-black-wopacity-rgb-png.png https://vaticanhealthtimes.com/article/910242449-kyverna-therapeutics-appoints-nadia-dac-seasoned-commercial-leader-in-neurology-and-rare-disease-as-chief-commercial-officer Vatican Health Times en PressRelease 2026-05-04T12:00:00+00:00 Kyverna Therapeutics Appoints Nadia Dac, Seasoned Commercial Leader in Neurology and Rare Disease, as Chief Commercial Officer https://ml.globenewswire.com/media/c166e9f5-941a-48b0-be17-c24d54785784/small/kyverna-primary-full-2-png.png https://vaticanhealthtimes.com/article/910242457-4dmt-to-participate-in-upcoming-investor-conferences Vatican Health Times en PressRelease 2026-05-04T12:00:00+00:00 4DMT to Participate in Upcoming Investor Conferences https://ml.globenewswire.com/media/027d40cf-145a-47b2-a0b8-823759376823/small/logo-2x-png.png https://vaticanhealthtimes.com/article/910242470-valitor-presents-preclinical-data-demonstrating-superior-durability-with-six-month-treatment-protocol-of-vltr-559-to-treat-wet-amd Vatican Health Times en PressRelease 2026-05-04T12:00:00+00:00 Valitor Presents Preclinical Data Demonstrating Superior Durability with Six-month Treatment Protocol of VLTR-559 to Treat Wet AMD https://ml.globenewswire.com/media/58da3c80-c616-4358-9bbe-2936ace96649/small/valitor-sidebyside-png.png https://vaticanhealthtimes.com/article/910242492-nanox-announces-distribution-agreement-with-nuviodx-to-support-deployment-of-nanox-arc-systems Vatican Health Times en PressRelease 2026-05-04T12:00:00+00:00 Nanox Announces Distribution Agreement with NuvioDx to Support Deployment of Nanox.ARC Systems https://ml.globenewswire.com/media/57c1ffd6-84b3-46b9-b9b3-76666e6ba5a2/small/nano-logo-002-jpg.jpg https://vaticanhealthtimes.com/article/910242493-bascom-palmer-eye-institute-presents-four-posters-on-rose-bengal-photodynamic-antimicrobial-therapy-at-arvo-2026-advancing-the-clinical-case-for Vatican Health Times en PressRelease 2026-05-04T12:00:00+00:00 Bascom Palmer Eye Institute Presents Four Posters on Rose Bengal Photodynamic Antimicrobial Therapy at ARVO 2026, Advancing the Clinical Case for Provectus’s VisiRose Subsidiary and Rose Bengal Sodium in Infectious Keratitis https://ml.globenewswire.com/media/7cd1d796-f4d3-43f7-8e2b-eb51dc04a073/small/new-logo-png.png https://vaticanhealthtimes.com/article/910242515-healthlynked-launches-new-consumer-platform-and-multi-site-digital-ecosystem-to-redefine-the-front-door-to-healthcare Vatican Health Times en PressRelease 2026-05-04T12:00:00+00:00 HealthLynked Launches New Consumer Platform and Multi-Site Digital Ecosystem to Redefine the Front Door to Healthcare https://ml.globenewswire.com/media/d46cdad7-4537-49b8-bd75-54331ac4ff32/small/get-better-faster-png.png https://vaticanhealthtimes.com/article/910242538-lifeward-announces-new-rewalk-data-presented-at-asia-2026-conference-demonstrating-a-comprehensive-longitudinal-safety-analysis-for-a-powered Vatican Health Times en PressRelease 2026-05-04T12:00:00+00:00 Lifeward Announces New ReWalk® Data Presented at ASIA 2026 Conference Demonstrating a Comprehensive Longitudinal Safety Analysis for a Powered Exoskeleton https://ml.globenewswire.com/media/9343d7ac-5bc7-4a60-a2c9-a41bf7b5e007/small/lifeward-full-logo-rgb-for-web-01-jpg.jpg https://vaticanhealthtimes.com/article/910242561-lenz-therapeutics-to-report-first-quarter-2026-financial-results-and-recent-corporate-highlights-on-may-11-2026-and-attend-upcoming-investor Vatican Health Times en PressRelease 2026-05-04T12:00:00+00:00 LENZ Therapeutics to Report First Quarter 2026 Financial Results and Recent Corporate Highlights on May 11, 2026 and Attend Upcoming Investor Conference https://ml.globenewswire.com/media/e058841a-d17f-4fd7-b817-0b2c8e6cb656/small/lenz-png.png https://vaticanhealthtimes.com/article/910242564-atsena-presents-positive-interim-six-month-results-from-part-b-of-phase-1-2-3-lighthouse-trial-evaluating-atsn-201-in-patients-with-x-linked Vatican Health Times en PressRelease 2026-05-04T12:00:00+00:00 Atsena Presents Positive Interim Six-Month Results from Part B of Phase 1/2/3 LIGHTHOUSE Trial Evaluating ATSN-201 in Patients with X-linked Retinoschisis https://ml.globenewswire.com/media/90d0bd84-4404-435c-9875-3473b4cc7172/small/atsena-logo-jpg.jpg https://vaticanhealthtimes.com/article/910242574-after-successful-fda-meeting-clene-filing-accelerated-approval-nda-for-als Vatican Health Times en PressRelease 2026-05-04T12:00:00+00:00 After Successful FDA Meeting, Clene Filing Accelerated Approval NDA for ALS https://ml.globenewswire.com/media/e9de96a4-582e-4975-8e43-6f3e6259c075/small/clene-logo-2x-png.png https://vaticanhealthtimes.com/article/910242578-akebia-therapeutics-announces-vadadustat-post-hoc-win-statistics-analysis-demonstrating-statistically-significant-reduction-in-mortality-and Vatican Health Times en PressRelease 2026-05-04T12:00:00+00:00 Akebia Therapeutics Announces Vadadustat Post-hoc Win Statistics Analysis Demonstrating Statistically Significant Reduction in Mortality and Hospitalization Composite Endpoint Published in the Journal of American Society of Nephrology https://ml.globenewswire.com/media/c7f3708e-3328-4668-95c6-e7646efd653a/small/akebia-logo-fullcolor-rgb-png.png https://vaticanhealthtimes.com/article/910242582-legend-biotech-expands-scientific-advisory-expertise-to-inform-future-growth Vatican Health Times en PressRelease 2026-05-04T12:00:00+00:00 Legend Biotech Expands Scientific Advisory Expertise to Inform Future Growth https://ml.globenewswire.com/media/d3a680c2-cab6-4eb2-9ed0-7be055f9e180/small/legend-logo-fullcolor-transparent-1-png.png https://vaticanhealthtimes.com/article/910242619-senseonics-enters-into-amended-loan-agreement-with-hercules-to-increase-borrowing-capacity-to-140-million Vatican Health Times en PressRelease 2026-05-04T12:00:00+00:00 Senseonics Enters Into Amended Loan Agreement with Hercules to Increase Borrowing Capacity to $140 Million https://ml.globenewswire.com/media/7f64f449-dd5d-4bd1-9504-82adb3846669/small/logo-png.png https://vaticanhealthtimes.com/article/910237928-emerging-drugs-market-to-reach-558-0-billion-by-2030-driven-by-biologics-innovation-and-regulatory-support Vatican Health Times en PressRelease 2026-05-04T11:34:01+00:00 Emerging Drugs Market to Reach $558.0 Billion by 2030, Driven by Biologics Innovation and Regulatory Support https://ml.globenewswire.com/media/d0c282b6-d496-45a8-a941-33fa5c3e824c/small/bcc-logo-1200-630-png.png https://vaticanhealthtimes.com/article/910237828-vera-therapeutics-to-participate-in-the-bank-of-america-securities-2026-health-care-conference Vatican Health Times en PressRelease 2026-05-04T11:30:00+00:00 Vera Therapeutics to Participate in the Bank of America Securities 2026 Health Care Conference https://ml.globenewswire.com/media/b5c9081c-e6d9-44f7-abd0-0997a3c713f2/small/vera-thumbnail-jpg.jpg https://vaticanhealthtimes.com/article/910237832-macrogenics-and-sagard-healthcare-partners-enter-into-expanded-zynyz-royalty-purchase-agreement Vatican Health Times en PressRelease 2026-05-04T11:30:00+00:00 MacroGenics and Sagard Healthcare Partners Enter into Expanded ZYNYZ® Royalty Purchase Agreement https://ml.globenewswire.com/media/72a7b58c-b7ca-4cd5-b2bb-185124351f1c/small/macrogenics-logo-transparent-background-png.png https://vaticanhealthtimes.com/article/910237835-entente-education-canada-honours-dr-roger-wong-with-award-for-eminent-contribution-to-older-adults-in-canada Vatican Health Times en PressRelease 2026-05-04T11:30:00+00:00 Entente Education Canada honours Dr. Roger Wong with Award for Eminent Contribution to Older Adults in Canada https://ml.globenewswire.com/media/YzNlOWZkNDctZThiZC00MzJjLTg2MmItM2U3ZTNhNzViYzJhLTUwMDE2MjAyOC0yMDI2LTA1LTA0LWVu/tiny/Entente-Education-Canada.png https://vaticanhealthtimes.com/article/910237841-bridgebio-to-present-new-acoramidis-data-on-disease-progression-biomarkers-and-clinical-outcomes-at-esc-heart-failure-2026 Vatican Health Times en PressRelease 2026-05-04T11:30:00+00:00 BridgeBio to Present New Acoramidis Data on Disease Progression, Biomarkers, and Clinical Outcomes at ESC-Heart Failure 2026 https://ml.globenewswire.com/media/2074ba9b-0e5b-41fa-baac-553f1345bb75/small/bridge-bio-black-png.png https://vaticanhealthtimes.com/article/910237849-kura-oncology-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4 Vatican Health Times en PressRelease 2026-05-04T11:30:00+00:00 Kura Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) https://ml.globenewswire.com/media/ebf510d7-3727-4cc8-894f-6ce2d82b941a/small/kura-logo-for-globe-newswire-prs-png.png https://vaticanhealthtimes.com/article/910237860-palvella-therapeutics-announces-first-patients-dosed-in-phase-2-lotu-trial-of-fast-track-designated-qtorin-rapamycin-for-clinically-significant Vatican Health Times en PressRelease 2026-05-04T11:30:00+00:00 Palvella Therapeutics Announces First Patients Dosed in Phase 2 LOTU Trial of Fast Track-Designated QTORIN™ Rapamycin for Clinically Significant Angiokeratomas https://ml.globenewswire.com/media/83fd569b-5e6c-46ad-882a-6430f8ab755a/small/palvella-2025-logo-new-jpg.jpg https://vaticanhealthtimes.com/article/910237878-inflarx-reports-favorable-reactive-metabolite-profile-for-izicopan-in-human-liver-microsomes Vatican Health Times en PressRelease 2026-05-04T11:30:00+00:00 InflaRx Reports Favorable Reactive Metabolite Profile for Izicopan in Human Liver Microsomes https://ml.globenewswire.com/media/e017df5c-9a9b-4f4f-9a94-6c2eeb0400bc/small/inflarx-logo-png.png https://vaticanhealthtimes.com/article/910237911-windward-bio-announces-165m-crossover-financing-to-advance-pipeline-of-long-acting-immunology-therapies-with-best-in-disease-potential Vatican Health Times en PressRelease 2026-05-04T11:30:00+00:00 Windward Bio Announces $165M Crossover Financing to Advance Pipeline of Long-Acting Immunology Therapies With Best-in-Disease Potential https://ml.globenewswire.com/media/Nzk5NDkzNGQtNWZiNi00MGZkLTg2ZTAtYzViNDkwNTJjOTVmLTUwMDEzMTYxMS0yMDI2LTA1LTA0LWVu/tiny/Windward-Bio.png https://vaticanhealthtimes.com/article/910237843-cartesian-therapeutics-announces-new-employment-inducement-grants Vatican Health Times en PressRelease 2026-05-04T11:05:00+00:00 Cartesian Therapeutics Announces New Employment Inducement Grants https://ml.globenewswire.com/media/2bf78841-be30-4bb5-bfb5-0b5f383f3302/small/cartesian-logo-color-png.png https://vaticanhealthtimes.com/article/910237845-nextcure-and-simcere-zaiming-initiate-dose-optimization-for-sim0505-cdh6-adc-in-gynecologic-cancers Vatican Health Times en PressRelease 2026-05-04T11:05:00+00:00 NextCure and Simcere Zaiming Initiate Dose Optimization for SIM0505 (CDH6 ADC) in Gynecologic Cancers https://ml.globenewswire.com/media/df24cd65-0f3d-4ede-9e7a-c3f58ce6e9d4/small/logo-nextcure-jpg.jpg https://vaticanhealthtimes.com/article/910237870-kraig-biocraft-laboratories-launches-april-may-production-cycle-following-record-spider-silk-output Vatican Health Times en PressRelease 2026-05-04T11:05:00+00:00 Kraig Biocraft Laboratories Launches April/May Production Cycle Following Record Spider Silk Output https://ml.globenewswire.com/media/3cf5ab91-0822-460b-bb13-17447941c84a/small/kblb-logo-jpg.jpg https://vaticanhealthtimes.com/article/910233626-pasithea-therapeutics-announces-appointment-of-kartik-krishnan-m-d-ph-d-as-chief-medical-officer Vatican Health Times en PressRelease 2026-05-04T11:01:00+00:00 Pasithea Therapeutics Announces Appointment of Kartik Krishnan, M.D., Ph.D. as Chief Medical Officer https://ml.globenewswire.com/media/0016f128-13c3-45a7-8455-cec1f4768995/small/pasithealogo-png.png https://vaticanhealthtimes.com/article/910233519-ardena-strengthens-executive-team-to-drive-its-next-phase-of-growth Vatican Health Times en PressRelease 2026-05-04T11:00:00+00:00 Ardena Strengthens Executive Team to Drive its Next Phase of Growth https://ml-eu.globenewswire.com/media/eddef504-18ee-4f10-8442-9e61ef77e262/medium/ardena-appoints-cfo-and-cco.png https://vaticanhealthtimes.com/article/910233520-indivior-announces-175-million-accelerated-share-repurchase Vatican Health Times en PressRelease 2026-05-04T11:00:00+00:00 Indivior Announces $175 Million Accelerated Share Repurchase https://ml-eu.globenewswire.com/media/42de3285-90ea-4020-a3ad-25f71026b41a/small/indivior-logo-jpg.jpg https://vaticanhealthtimes.com/article/910233590-biocryst-announces-european-licensing-agreement-with-irish-affiliate-of-neopharmed-gentili-for-navenibart-in-hereditary-angioedema Vatican Health Times en PressRelease 2026-05-04T11:00:00+00:00 BioCryst Announces European Licensing Agreement with Irish Affiliate of Neopharmed Gentili for Navenibart in Hereditary Angioedema https://ml.globenewswire.com/media/8b033909-1a3c-4811-b07b-fe03b12e00d2/small/biocryst-primarylogo-r-2c-rgb-jpg.jpg https://vaticanhealthtimes.com/article/910233621-tenax-therapeutics-appoints-timothy-healey-mba-as-chief-commercial-officer Vatican Health Times en PressRelease 2026-05-04T11:00:00+00:00 Tenax Therapeutics Appoints Timothy Healey, MBA as Chief Commercial Officer https://ml.globenewswire.com/media/d8c1d3b1-51a5-4835-a9e8-6d5bce14917e/small/tenax-logo-rgb-color-jpg.jpg https://vaticanhealthtimes.com/article/910233623-netramark-appoints-dr-panteli-theocharous-as-fractional-chief-medical-officer-strengthening-clinical-leadership-to-accelerate-global-adoption-of Vatican Health Times en PressRelease 2026-05-04T11:00:00+00:00 NetraMark Appoints Dr. Panteli Theocharous As Fractional Chief Medical Officer, Strengthening Clinical Leadership To Accelerate Global Adoption of NetraAI https://ml.globenewswire.com/media/d65cf3f8-cf9c-475c-b740-09a659269da4/small/netramark-word-eye-blk-jpg.jpg https://vaticanhealthtimes.com/article/910233629-krystal-biotech-announces-first-quarter-2026-financial-and-operating-results Vatican Health Times en PressRelease 2026-05-04T11:00:00+00:00 Krystal Biotech Announces First Quarter 2026 Financial and Operating Results https://ml.globenewswire.com/media/94ec1f39-c0eb-4e65-9d7e-250519ef03f4/small/krys-logo-nobackground-with-registered-symbol-png.png https://vaticanhealthtimes.com/article/910233642-10-barrel-brewing-launches-clean-slate-and-salty-sips-expanding-rtd-line-with-functional-n-a-and-low-sugar-cocktails Vatican Health Times en PressRelease 2026-05-04T11:00:00+00:00 10 Barrel Brewing Launches Clean Slate and Salty Sips, Expanding RTD Line with Functional N/A and Low-Sugar Cocktails https://ml.globenewswire.com/media/5e71b27b-1cc8-4780-8689-8d8d6ae86236/medium/clean-slate-and-salty-sips.png https://vaticanhealthtimes.com/article/910233645-seres-therapeutics-presents-preclinical-data-at-digestive-disease-week-ddw-2026-supporting-ser-603-a-next-generation-cultivated-live-biotherapeutic Vatican Health Times en PressRelease 2026-05-04T11:00:00+00:00 Seres Therapeutics Presents Preclinical Data at Digestive Disease Week (DDW) 2026 Supporting SER-603, a Next-Generation Cultivated Live Biotherapeutic Candidate, for Inflammatory Bowel Disease https://ml.globenewswire.com/media/f8c3ad50-d1a3-457d-b0c7-8f9237db7f93/small/seres-logo-png.png https://vaticanhealthtimes.com/article/910233649-centrum-launches-newly-reformulated-adults-50-complete-multivitamin-with-clinically-shown-cognitive-benefits Vatican Health Times en PressRelease 2026-05-04T11:00:00+00:00 Centrum Launches Newly Reformulated Adults 50+ Complete Multivitamin with Clinically Shown Cognitive Benefits https://ml.globenewswire.com/media/395df94a-8079-4f58-9b54-df434e56ec33/medium/centrum-adults-50-complete-multivitamin.png https://vaticanhealthtimes.com/article/910233653-centrum-lance-sa-multivitamine-compl-te-adultes-50-nouvellement-reformul-e-avec-des-bienfaits-cognitifs-d-montr-s-cliniquement Vatican Health Times en PressRelease 2026-05-04T11:00:00+00:00 Centrum lance sa multivitamine complète Adultes 50+ nouvellement reformulée avec des bienfaits cognitifs démontrés cliniquement https://ml.globenewswire.com/media/abbbfaf3-e52b-413c-9ded-52f74cf50911/medium/centrum-multivitamine-complete-pour-adultes-50.png https://vaticanhealthtimes.com/article/910233661-genyro-announces-new-paper-demonstrating-how-sidewinder-technology-democratizes-dna-construction-at-scale-and-facilitates-ai-driven-protein-design Vatican Health Times en PressRelease 2026-05-04T11:00:00+00:00 Genyro Announces New Paper Demonstrating How Sidewinder Technology Democratizes DNA Construction at Scale and Facilitates AI-Driven Protein Design https://ml.globenewswire.com/media/346f123b-cc5d-4de0-a31f-9c4f1315c070/medium/genyro-co-founders.jpg https://vaticanhealthtimes.com/article/910233678-seer-announces-appointment-of-anthony-bazarko-as-chief-commercial-officer Vatican Health Times en PressRelease 2026-05-04T11:00:00+00:00 Seer Announces Appointment of Anthony Bazarko as Chief Commercial Officer https://ml.globenewswire.com/media/ecdddbc3-8a58-4cba-a4a1-33971e79339a/medium/anthony-bazarko.jpg https://vaticanhealthtimes.com/article/910233683-istios-health-partners-with-care-id-to-expand-national-infectious-disease-clinical-research-network Vatican Health Times en PressRelease 2026-05-04T11:00:00+00:00 Istios Health Partners with CARE-ID to Expand National Infectious Disease Clinical Research Network https://ml.globenewswire.com/media/MTI0OGVmYTMtNmZkNC00ODA4LWJlNzUtNTYxODJlODcxNDBmLTEzMTYxMjEtMjAyNi0wNS0wNC1lbg==/tiny/Istios-Health.png https://vaticanhealthtimes.com/article/910233687-adma-biologics-announces-fda-approval-to-expand-the-label-for-asceniv-to-include-pediatric-immune-compromised-patients-two-years-of-age-and-older Vatican Health Times en PressRelease 2026-05-04T11:00:00+00:00 ADMA Biologics Announces FDA Approval to Expand the Label for ASCENIV™ to Include Pediatric Immune Compromised Patients Two Years of Age and Older https://ml.globenewswire.com/media/468b61b4-73b9-495e-a4be-f4823782b2fd/small/adma-biologics-rgb-l-092115p-jpg.jpg https://vaticanhealthtimes.com/article/910233701-axsome-therapeutics-reports-first-quarter-2026-financial-results-and-provides-business-update Vatican Health Times en PressRelease 2026-05-04T11:00:00+00:00 Axsome Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Update https://ml.globenewswire.com/media/1186f248-bfb6-4258-a391-f2ffd94c5d76/small/axsome-r-morpheus-logo-pos-rgb-png.png https://vaticanhealthtimes.com/article/910233704-cabaletta-bio-announces-pricing-of-150-million-underwritten-offering Vatican Health Times en PressRelease 2026-05-04T10:35:54+00:00 Cabaletta Bio Announces Pricing of $150 Million Underwritten Offering https://ml.globenewswire.com/media/44175396-6bbb-435f-b037-54a4052160d4/small/cabaletta-bio-registered-logo-png.png https://vaticanhealthtimes.com/article/910224348-aura-biosciences-announces-proposed-public-offering-of-common-stock-and-pre-funded-warrants Vatican Health Times en PressRelease 2026-05-04T10:03:00+00:00 Aura Biosciences Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants https://ml.globenewswire.com/media/92103c30-8e5a-4502-9ec4-0f3b3bd9bb83/small/aura-biosciences-1c-orange-large-jpg.jpg https://vaticanhealthtimes.com/article/910224335-aura-biosciences-announces-ceo-transition-as-company-advances-phase-3-compass-trial-toward-enrollment-completion Vatican Health Times en PressRelease 2026-05-04T10:01:00+00:00 Aura Biosciences Announces CEO Transition as Company Advances Phase 3 CoMpass Trial Toward Enrollment Completion https://ml.globenewswire.com/media/92103c30-8e5a-4502-9ec4-0f3b3bd9bb83/small/aura-biosciences-1c-orange-large-jpg.jpg https://vaticanhealthtimes.com/article/910224339-holland-bloorview-kids-rehabilitation-hospital-receives-475-000-commitment-from-td-bank-group-to-support-youth-with-disabilities Vatican Health Times en PressRelease 2026-05-04T10:00:00+00:00 Holland Bloorview Kids Rehabilitation Hospital receives $475,000 commitment from TD Bank Group to support youth with disabilities https://ml.globenewswire.com/media/YjY1NmY0MjktNjNkNy00MjI4LTgwNDYtZWJjZmRmYTgyZmI0LTExMDQ5NDUtMjAyNi0wNS0wNC1lbg==/tiny/Holland-Bloorview-Kids-Rehabil.png https://vaticanhealthtimes.com/article/910224345-scilex-holding-company-announces-its-board-of-directors-approved-may-26-2026-as-the-payment-date-of-the-previously-announced-dividend-of-dream-bowl Vatican Health Times en PressRelease 2026-05-04T10:00:00+00:00 Scilex Holding Company Announces Its Board of Directors Approved May 26, 2026 as the Payment Date of the Previously Announced Dividend of Dream Bowl Meme Coin I Tokens to Record Holders of Common Stock and other Eligible Equity Securities as of the… https://ml.globenewswire.com/media/e2f985bf-0880-4d05-8838-90a69c888cf9/small/logo-jpg.jpg https://vaticanhealthtimes.com/article/910220606-mother-s-day-gifting-is-changing-from-symbolic-presents-to-meaningful-relief-bob-and-brad-marks-the-occasion-with-up-to-30-off-wellness-devices Vatican Health Times en PressRelease 2026-05-04T09:10:38+00:00 Mother’s Day Gifting Is Changing: From Symbolic Presents to Meaningful Relief — Bob and Brad Marks the Occasion with Up to 30% Off Wellness Devices https://ml.globenewswire.com/media/b55bca4c-0fac-4226-9f7d-2e4b7b3e94e0/medium/mother-s-day-gifts-2026.png https://vaticanhealthtimes.com/article/910150844-novelty-nobility-taps-agc-biologics-to-further-develop-bispecific-drug-candidate Vatican Health Times en PressRelease 2026-05-04T00:00:00+00:00 Novelty Nobility Taps AGC Biologics to Further Develop Bispecific Drug Candidate https://ml.globenewswire.com/media/cecf4f80-22df-4bbf-b0a7-f50b9acf9495/medium/agc-biologics-and-novelty-nobility-representatives-meet.png https://vaticanhealthtimes.com/article/910150881-agc Vatican Health Times en PressRelease 2026-05-04T00:00:00+00:00 ノベルティ・ノビリティ、AGCバイオロジクスと提携し、二重特異性抗体候補薬の開発を推進 https://ml.globenewswire.com/media/NWUzMzQxMTYtZjcyYS00YjQ4LWE2ODYtY2ZiNWE0YTlmM2MzLTEzMTU5MjMtMjAyNi0wNS0wNC1qYQ==/tiny/AGC-Biologics-Inc-.png https://vaticanhealthtimes.com/article/910150885-novelty-nobility-agc-biologics Vatican Health Times en PressRelease 2026-05-04T00:00:00+00:00 노벨티 노빌리티 (Novelty Nobility), 이중특이성 항체 개발 위해 AGC Biologics와 협력 확대 https://ml.globenewswire.com/media/NWUzMzQxMTYtZjcyYS00YjQ4LWE2ODYtY2ZiNWE0YTlmM2MzLTEzMTU5MjMtMjAyNi0wNS0wNC1rbw==/tiny/AGC-Biologics-Inc-.png https://vaticanhealthtimes.com/article/910117015-caphra-urges-policymakers-to-expand-the-tobacco-cessation-toolkit Vatican Health Times en PressRelease 2026-05-03T19:00:00+00:00 CAPHRA Urges Policymakers to Expand the Tobacco Cessation Toolkit https://ml.globenewswire.com/media/6dc95f2d-65fb-409f-aed4-9ebe55554004/small/picture1-png.png https://vaticanhealthtimes.com/article/909983104-northeast-ohio-medical-university-neomed-celebrates-306-new-graduates-at-commencement-ceremony Vatican Health Times en PressRelease 2026-05-02T22:07:03+00:00 Northeast Ohio Medical University (NEOMED) Celebrates 306 New Graduates at Commencement Ceremony https://ml.globenewswire.com/media/MDgwNDNmM2ItZGZiNi00NTRjLTgzZTUtMDg3MjZjNjY0NGIyLTUwMDE1MDkxOS0yMDI2LTA1LTAyLWVu/tiny/Northeast-Ohio-Medical-Univers.png https://vaticanhealthtimes.com/article/909978301-memopryl-gets-reviewed-complete-formula-evaluation-of-ingredient-claims-and-side-effects-risk Vatican Health Times en PressRelease 2026-05-02T21:25:47+00:00 MemoPryl Gets Reviewed: Complete Formula Evaluation of Ingredient Claims and Side Effects Risk https://zingfast.com/wp-content/uploads/2026/05/MemoPryl-Reviews.jpg https://vaticanhealthtimes.com/article/909972974-visiocore-claims-evaluated-the-8-second-amazonian-morning-flush-for-crystal-clear-vision-support Vatican Health Times en PressRelease 2026-05-02T20:50:28+00:00 VisioCore Claims Evaluated: The 8-Second Amazonian Morning Flush For Crystal Clear Vision Support https://zingfast.com/wp-content/uploads/2026/05/VisioCore-Supplement.jpg https://vaticanhealthtimes.com/article/909966566-halo-care-skin-tag-remover-claims-evaluated-the-strongest-most-effective-mole-skin-tag-corrector-serum Vatican Health Times en PressRelease 2026-05-02T20:14:38+00:00 Halo Care Skin Tag Remover Claims Evaluated: The Strongest, Most Effective Mole & Skin Tag Corrector Serum https://zingfast.com/wp-content/uploads/2026/05/Halo-Care-Skin-Tag-Remover.jpg https://vaticanhealthtimes.com/article/909933274-milken-institute-global-conference-2026-set-to-open-tomorrow-in-beverly-hills-with-kfsh-participation Vatican Health Times en PressRelease 2026-05-02T16:00:00+00:00 Milken Institute Global Conference 2026 Set to Open Tomorrow in Beverly Hills with KFSH Participation https://ml.globenewswire.com/media/9f73a943-28c0-4ee7-a796-2407051abbe7/small/logo-kfshrc-png.png https://vaticanhealthtimes.com/article/909933276-la-milken-institute-global-conference-2026-se-inaugura-ma-ana-en-beverly-hills-con-la-participaci-n-de-kfsh Vatican Health Times en PressRelease 2026-05-02T16:00:00+00:00 La Milken Institute Global Conference 2026 se inaugura mañana en Beverly Hills con la participación de KFSH https://ml.globenewswire.com/media/9f73a943-28c0-4ee7-a796-2407051abbe7/small/logo-kfshrc-png.png https://vaticanhealthtimes.com/article/909933282-tem-in-cio-amanh-em-beverly-hills-a-milken-institute-global-conference-2026-com-a-participa-o-do-kfsh Vatican Health Times en PressRelease 2026-05-02T16:00:00+00:00 Tem Início Amanhã em Beverly Hills a Milken Institute Global Conference 2026 com a Participação do KFSH https://ml.globenewswire.com/media/9f73a943-28c0-4ee7-a796-2407051abbe7/small/logo-kfshrc-png.png